A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Summary

The purpose of this study will be to evaluate efficacy and safety of Ruxolitinib cream in participants With Cutaneous Lichen Planus. This is randomized, double-blind, vehicle-controlled (DBVC) study with a DBVC period of 16 weeks followed by an open label period (OLE) period of 16 weeks.

Timeline

Start

2022-11-23

Primary completion

2023-10-02

Completion

2024-02-26

Outcome

Met primary endpoint

registry analysis (superiority test); Double-Blind, Vehicle-Controlled Period: Ruxolitinib Cream 1.5% BID vs Double-Blind, Vehicle-Controlled Period: Vehicle Cream BID; p = 0.0129 NCT05593432 ↗

Drugs

Indications